Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the second-most frequent drug type to cause hypersensitivity reactions in children. Asthma is one of the risk factors for NSAID hypersensitivity (NSAID-H) in adult patients. There are limited number of studies evaluating NSAID-H among children with asthma. Our aim was to assess the frequency of confirmed NSAID-H and evaluate the classification of NSAID-H in children with asthma. Methods: Patients followed with a diagnosis of asthma in our Pediatric Allergy Clinic were evaluated for NSAID-H. Patients were questioned whether they had used NSAIDs, and if they experienced any reaction with these drugs. A control group was also questioned for reactions to NSAID use. Results: 976 children with asthma and 2,000 healthy children as a control group were included in this study. The mean age of the patients with asthma was 10.61 ± 4.21 years and 59.5% were male. Ten (1%) had a reaction history to NSAIDs. NSAID-H was confirmed in 9 (0.9%) who were tested with the suspected drugs. Six of these were classified as “single NSAID-induced urticaria/angioedema or anaphylaxis” and 3 were classified as “NSAIDs-exacerbated respiratory disease.” In the control group, only 1 subject had a reaction history to acetylsalicylic acid and no reaction developed in the provocation test. Conclusions: In our study, NSAID-H was found more frequent in children with asthma than in the control group. Children with asthma should be evaluated for reactions to NSAIDs during hospital visits.

Keywords:
Asthma, Children, Drug provocation test, Hypersensitivity, Nonsteroidal anti-inflammatory drugs
1.
Ortega N, Doña I, Moreno E, Audicana MT, Barasona MJ, Berges-Gimeno MP, Blanca-Lopez N, Lobera T, Padial A, Rosado A, Torres MJ: Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2014; 24: 308–323.
2.
Doña I, Blanca-López N, Torres MJ, García-Campos J, García-Núñez I, Gómez F, Salas M, Rondón C, Canto MG, Blanca M: Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol 2012; 22: 363–371.
3.
Torres MJ, Barrionuevo E, Kowalski M, Blanca M: Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 2014; 34: 507–524.
4.
Settipane RA, Constantine HP, Settipane GA: Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy 1980; 35: 149–154.
5.
Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66: 818–829.
6.
Jenkins C, Costello J, Hodge L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328: 434.
7.
Schuhl JF, Pereyra JG: Oral acetylsalicylic acid (aspirin) challenge in asthmatic children. Clin Allergy 1979; 9: 83–88.
8.
Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ: The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study. J Pediatr 2005; 147: 233–238.
9.
Vedanthan PK, Menon MM, Bell TD, Bergin D: Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma. J Allergy Clin Immunol 1977; 60: 8–13.
10.
Towns SJ, Mellis CM: Role of acetyl salicylic acid and sodium metabisulfite in chronic childhood asthma. Pediatrics 1984; 73: 631–637.
11.
Rachelefsky GS, Coulson A, Siegel SC, Stiehm ER: Aspirin intolerance in chronic childhood asthma: detected by oral challenge. Pediatrics 1975; 56: 443–448.
12.
Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention (updated 2017). http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/.
13.
Demoly P, Kropf R, Bircher A, Pichler WJ: Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy 1999; 54: 999–1003.
14.
Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al; ENDA/EAACI Drug Allergy Interest Group: Skin test concentrations for systemically administered drugs: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68: 702–712.
15.
Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P: General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45–51.
16.
Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P; European Network for Drug Allergy (ENDA); EAACI Interest Group on Drug Hypersensitivity: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854–863.
17.
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G, et al: EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62: 1111–1118.
18.
Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al: Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013; 68: 1219–1232.
19.
Zambonino MA, Torres MJ, Muñoz C, Requena G, Mayorga C, Posadas T, Urda A, Blanca M, Corzo JL: Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. Pediatr Allergy Immunol 2013; 24: 151–159.
20.
Vezir E, Erkocoglu M, Civelek E, Kaya A, Azkur D, Akan A, Ozcan C, Toyran M, Ginis T, Misirlioglu ED, Kocabas CN: The evaluation of drug provocation tests in pediatric allergy clinic: a single center experience. Allergy Asthma Proc 2014; 35: 156–162.
21.
Guvenir H, Dibek Misirlioglu E, Vezir E, Toyran M, Ginis T, Civelek E, Kocabas CN: Nonsteroidal anti-inflammatory drug hypersensitivity among children. Allergy Asthma Proc 2015; 36: 386–393.
22.
Cavkaytar O, Yilmaz EA, Karaatmaca B, Buyuktiryaki B, Sackesen C, Sekerel BE, Soyer O: Different phenotypes of non-steroidal anti-inflammatory drug hypersensitivity during childhood. Int Arch Allergy Immunol 2015; 167: 211–221.
23.
Yilmaz O, Ertoy Karagol IH, Bakirtas A, Topal E, Celik GE, Demirsoy MS, Turktas I: Challenge-proven nonsteroidal anti-inflammatory drug hypersensitivity in children. Allergy 2013; 68: 1555–1561.
24.
Soferman R, Tsivion A, Farber M, Sivan Y: The effect of a single dose of acetaminophen on airways response in children with asthma. Clin Pediatr 2013; 52: 42–48.
25.
Modena B, White AA, Woessner KM: Aspirin and nonsteroidal antiinflammatory drugs hypersensitivity and management. Immunol Allergy Clin North Am 2017; 37: 727–749.
26.
Szczeklik A, Nizankowska E, Duplaga M: Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16: 432–436.
27.
Rajan JP, Wineinger NE, Stevenson DD, White AA: Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 2015; 135: 676–681.
© S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.